Literature DB >> 6875521

Immune responses in serum and respiratory secretions following vaccination with a live cold-recombinant (CR35) and inactivated A/USSR/77 (H1N1) influenza virus vaccine.

J M Zahradnik, J A Kasel, R R Martin, H R Six, T R Cate.   

Abstract

One hundred adult volunteers were administered inactivated vaccine (20 micrograms/0.5 cc) intramuscularly (IM) or intranasally (IN), or 10(4.7) TCID50 of a live cold-adapted vaccine (CR35) IN. Microneutralization (Nt) and radioimmunoprecipitation methods were employed to measure hemagglutinin antibody responses in sera, nasal washes, and in bronchopulmonary lavage fluids. In unprimed recipients, the relative frequency of serum antibody response and magnitude of rise was highest following the IM-inactivated vaccine (100%) and lowest after IN-live vaccine (29%). However, in individuals with pre-existing antibody, the three vaccines given were comparably immunogenic. Occurrences of secretory IgA hemagglutinin antibody in nasal washings were more frequently associated with topical administration of live or inactivated vaccine, whereas, IgG hemagglutinin antibody responses occurred with equal frequency in nasal washings in all three vaccine groups. Analysis of the hemagglutinin antibody responses in the lower respiratory tract showed that the IN-live vaccine favored the induction of secretory IgA hemagglutinin antibody and the IM-inactivated vaccine stimulated a more frequent IgG hemagglutinin antibody response.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6875521     DOI: 10.1002/jmv.1890110403

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  10 in total

1.  In elderly persons live attenuated influenza A virus vaccines do not offer an advantage over inactivated virus vaccine in inducing serum or secretory antibodies or local immunologic memory.

Authors:  D C Powers; L F Fries; B R Murphy; B Thumar; M L Clements
Journal:  J Clin Microbiol       Date:  1991-03       Impact factor: 5.948

Review 2.  Is there a role for a mucosal influenza vaccine in the elderly?

Authors:  E M Corrigan; R L Clancy
Journal:  Drugs Aging       Date:  1999-09       Impact factor: 3.923

3.  Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine.

Authors:  M L Clements; B R Murphy
Journal:  J Clin Microbiol       Date:  1986-01       Impact factor: 5.948

Review 4.  Mucosal vaccines for the prevention of influenza.

Authors:  R L Clancy
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

5.  Systemic and local antibody responses in elderly subjects given live or inactivated influenza A virus vaccines.

Authors:  D C Powers; S D Sears; B R Murphy; B Thumar; M L Clements
Journal:  J Clin Microbiol       Date:  1989-12       Impact factor: 5.948

6.  Influenza vaccination in older patients. Immunogenicity, epidemiology and available agents.

Authors:  H Glathe; W Lange
Journal:  Drugs Aging       Date:  1995-05       Impact factor: 3.923

7.  High doses of purified influenza A virus hemagglutinin significantly augment serum and nasal secretion antibody responses in healthy young adults.

Authors:  W A Keitel; R B Couch; T R Cate; K R Hess; B Baxter; J M Quarles; R L Atmar; H R Six
Journal:  J Clin Microbiol       Date:  1994-10       Impact factor: 5.948

8.  Analysis of immunoglobulin G antibody responses after administration of live and inactivated influenza A vaccine indicates that nasal wash immunoglobulin G is a transudate from serum.

Authors:  D K Wagner; M L Clements; C B Reimer; M Snyder; D L Nelson; B R Murphy
Journal:  J Clin Microbiol       Date:  1987-03       Impact factor: 5.948

9.  Local and systemic antibody responses in high-risk adults given live-attenuated and inactivated influenza A virus vaccines.

Authors:  G J Gorse; R B Belshe; N J Munn
Journal:  J Clin Microbiol       Date:  1988-05       Impact factor: 5.948

10.  Assessing mathematical models of influenza infections using features of the immune response.

Authors:  Hana M Dobrovolny; Micaela B Reddy; Mohamed A Kamal; Craig R Rayner; Catherine A A Beauchemin
Journal:  PLoS One       Date:  2013-02-28       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.